Treatment Sequencing Strategies in R/R Multiple Myeloma

home / training-academy / treatment-sequencing-strategies-in-rr-multiple-myeloma

A panel of experts on relapsed/refractory multiple myeloma review clinical trial data on novel therapies and drug combinations and discuss treatment decision-making and sequencing practices.

EP. 1: Clinical Scenario 1: A 67-Year-Old Man with Multiple Myeloma

Peter Voorhees, MD;Shaji Kumar, MD, Mayo Clinic;Ariel Grajales-Cruz, MD;Thomas G. Martin, MD

September 20th 2024

A panel of myeloma specialists review the case of a 67-year-old patient with multiple myeloma (MM) who received a bispecific antibody.

EP. 2: Treatment Options in Late-line R/R MM Patients

Peter Voorhees, MD;Shaji Kumar, MD, Mayo Clinic;Ariel Grajales-Cruz, MD;Thomas G. Martin, MD

September 20th 2024

Following the presentation of a case of a patient with multiple myeloma, the panel have a roundtable discussion on how to approach treatment.

EP. 3: Sequencing Options of Bispecifics in R/R MM

Peter Voorhees, MD;Shaji Kumar, MD, Mayo Clinic;Ariel Grajales-Cruz, MD;Thomas G. Martin, MD

September 27th 2024

Focusing on treatment paradigms for patients with relapsed/refractory multiple myeloma, the expert panel discusses the role of BCMA-targeted bispecifics and how they might consider sequencing therapies.

EP. 4: Pooled Analysis from MagnetisMM Studies

Peter Voorhees, MD;Shaji Kumar, MD, Mayo Clinic;Ariel Grajales-Cruz, MD;Thomas G. Martin, MD

October 4th 2024

Thomas G. Martin, MD, reviews findings from a pooled analysis from MagnetisMM that evaluated elranatamab in patients with relapsed/refractory MM who received prior BCMA-directed therapies.

EP. 5: Consideration in Treatment Selection and Sequencing in R/R MM

Peter Voorhees, MD;Shaji Kumar, MD, Mayo Clinic;Ariel Grajales-Cruz, MD;Thomas G. Martin, MD

October 11th 2024

The panel discusses how they approach treatment selection and sequencing for patients with relapsed/refractory multiple myeloma.

EP. 6: Clinical Scenario 2: A 70-Year-Old Male with R/R MM

Peter Voorhees, MD;Shaji Kumar, MD, Mayo Clinic;Ariel Grajales-Cruz, MD;Thomas G. Martin, MD

October 11th 2024

Shaji Kumar, MD, presents the case of a 70-year-old patient with relapsed/refractory multiple myeloma who received CAR T-cell therapy.

EP. 7: Treatment Options for Late-line R/R MM

Peter Voorhees, MD;Shaji Kumar, MD, Mayo Clinic;Ariel Grajales-Cruz, MD;Thomas G. Martin, MD

October 18th 2024

Following the presentation of a case of a patient with relapsed/refractory multiple myeloma, the expert panel reviews treatment options.

EP. 8: Overview of CAR-T Sequencing Strategies in R/R MM

Peter Voorhees, MD;Shaji Kumar, MD, Mayo Clinic;Ariel Grajales-Cruz, MD;Thomas G. Martin, MD

October 18th 2024

Shaji Kumar, MD, reviews data from cohort C of CARTITUDE-2 and a real-world study evaluating ide-cel in patients with relapsed/refractory multiple myeloma.

EP. 9: Challenges in Optimizing Sequencing

Peter Voorhees, MD;Shaji Kumar, MD, Mayo Clinic;Ariel Grajales-Cruz, MD;Thomas G. Martin, MD

October 25th 2024

Experts on multiple myeloma outline current challenges in determining the optimal treatment strategy for patients with relapsed/refractory disease who are eligible for bispecifics and CAR T-cell therapy.

EP. 10: Future Clinical Trials: Sequencing Decisions for Bispecifics and CAR T-Cell Therapy

Peter Voorhees, MD;Shaji Kumar, MD, Mayo Clinic;Ariel Grajales-Cruz, MD;Thomas G. Martin, MD

October 25th 2024

Shaji Kumar, MD, reviews data from cohort C of CARTITUDE-2 and a real-world study evaluating ide-cel in patients with relapsed/refractory multiple myeloma.

EP. 11: Challenges in Optimizing Sequencing Strategies in R/R MM

Peter Voorhees, MD;Shaji Kumar, MD, Mayo Clinic;Ariel Grajales-Cruz, MD;Thomas G. Martin, MD

November 1st 2024

EP. 12: Unmet Needs and Future Perspectives in Treatment Sequencing Strategies in R/R MM

Peter Voorhees, MD;Shaji Kumar, MD, Mayo Clinic;Ariel Grajales-Cruz, MD;Thomas G. Martin, MD

November 1st 2024

The panel concludes its discussion with key takeaways on unmet needs and evolving treatment paradigms in relapsed/refractory multiple myeloma.